用JAK抑制剂治疗的风湿性关节炎患者的临床和超声波缓解:现实世界的研究
Carmen Lasa-Teja1, Juan José Fernández-Cabero2, Lara Sánchez-Bilbao1
1Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, Instituto de Investigación Valdecilla (IDIVAL), 39008 Santander, Spain.
Journal of clinical medicine
|January 10, 2026
概括
简氏激酶抑制剂 (JAKi) 有效治疗类风湿性关节炎 (RA). 超声波成像显示,虽然许多患者实现了临床缓解,但有些人仍然患有活跃的突炎,这凸显了在RA治疗中需要客观监测的必要性.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 医疗成像医学成像
背景情况:
- 雅努斯激酶抑制剂 (JAKi) 已被批准用于类风湿性关节炎 (RA) 治疗,旨在实现临床缓解.
- 像DAS28-CRP这样的复合分数可以是主观的;超声波提供了对突活动的客观评估.
- 雅克抑制剂可能会影响炎症之外的RA维度.
研究的目的:
- 评估在常规护理下用JAK抑制剂治疗的RA患者的临床和超声波定义缓解.
- 为了比较不同JAK抑制剂在实现缓解方面的疗效.
主要方法:
- 与巴里西提尼布,菲尔戈提尼布,托法西提尼布或乌帕达西提尼布治疗的RA患者的横截面研究.
- 通过DAS28-CRP定义的临床缓解;超声波缓解定义在32个关节没有功率多普勒信号.
- 在2022年11月至2023年4月期间收集的数据.
主要成果:
- 包括78名RA患者,87.2%为女性,平均年龄59.5岁,疾病持续时间10.6年.
- 临床缓解率为42.3%,超声波缓解率为56.4%;JAKi之间没有显著差异.
- 根据任何定义,有60%的缓解期患者满足了这两个标准;22%的患者仅有超声波缓解,18%的患者仅有临床缓解.
结论:
- 在RA患者中,JAK抑制剂有效地实现了缓解.
- 超声波检测到临床缓解患者的残留突炎和其他人的沉默缓解,帮助个性化治疗.
- 在常规实践中,在JAK抑制剂之间没有观察到显著的临床或超声波差异.
相关概念视频
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
470
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
470
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
Rheumatic Heart Disease III: Medical Management
277
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
277
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
423
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
423


